| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Skye Bioscience, Inc. | Director, 10%+ Owner | Common Stock | 8.17M | $28.3M | $3.46 | Aug 21, 2025 | By 5AM Ventures VII, L.P. |
| Enliven Therapeutics, Inc. | Director, 10%+ Owner | Common Stock | 960K | $14.5M | $15.14 | Feb 23, 2023 | Indirect |
| Camp4 Therapeutics Corp | Director, 10%+ Owner | Common Stock | 2.63M | $5.3M | $2.02 | Sep 11, 2025 | By 5AM Ventures VI, L.P. |
| Skye Bioscience, Inc. | Director, 10%+ Owner | Common Stock | 1.46M | $4.98M | $3.42 | Aug 22, 2025 | By 5AM Ventures II, L.P. |
| Camp4 Therapeutics Corp | Director, 10%+ Owner | Common Stock | 2.94M | $4.5M | $1.53 | Sep 11, 2025 | By 5AM Ventures VII, L.P. |
| Camp4 Therapeutics Corp | Director, 10%+ Owner | Common Stock | 303K | $612K | $2.02 | Sep 11, 2025 | By 5AM Opportunities II, L.P. |
| Skye Bioscience, Inc. | Director, 10%+ Owner | Common Stock | 57.5K | $197K | $3.42 | Aug 22, 2025 | By 5AM Co-Investors II, L.P. |
| Skye Bioscience, Inc. | Director, 10%+ Owner | Stock Option (Right to Buy) | 35K | $1.19K | $0.02 | Feb 24, 2025 | Direct |
| Pear Therapeutics, Inc. | Director, 10%+ Owner | Class A Common Stock | 14.6M | Dec 3, 2021 | by 5AM Ventures IV, L.P. | ||
| Pear Therapeutics, Inc. | Director, 10%+ Owner | Class A Common Stock | 3.37M | Dec 3, 2021 | by 5AM Opportunities I, L.P. | ||
| Pear Therapeutics, Inc. | Director, 10%+ Owner | Class A Common Stock | 610K | Dec 3, 2021 | by 5AM Co-Investors IV, L.P. | ||
| Enliven Therapeutics, Inc. | Director, 10%+ Owner | Stock Option (right to buy) | 27.6K | Feb 23, 2023 | Direct | ||
| Camp4 Therapeutics Corp | Director, 10%+ Owner | Stock Option (Right to Buy) | 9K | Jun 25, 2025 | Direct | ||
| Camp4 Therapeutics Corp | Director, 10%+ Owner | Series A Prime Preferred Stock | 0 | Oct 15, 2024 | Indirect | ||
| Camp4 Therapeutics Corp | Director, 10%+ Owner | Series B Preferred Stock | 0 | Oct 15, 2024 | Indirect |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| CAMP | Camp4 Therapeutics Corp | Sep 11, 2025 | 1 | $4.5M | 4 | Sep 15, 2025 | Director, 10%+ Owner |
| SKYE | Skye Bioscience, Inc. | Aug 21, 2025 | 4 | -$801K | 4 | Aug 22, 2025 | Director, 10%+ Owner |
| CAMP | Camp4 Therapeutics Corp | Jun 25, 2025 | 1 | $0 | 4 | Jun 27, 2025 | Director, 10%+ Owner |
| SKYE | Skye Bioscience, Inc. | Feb 24, 2025 | 1 | $0 | 4 | Feb 26, 2025 | Director |
| SKYE | Skye Bioscience, Inc. | Oct 28, 2024 | 1 | $0 | 4 | Oct 30, 2024 | Director |
| CAMP | Camp4 Therapeutics Corp | Oct 15, 2024 | 7 | $10M | 4 | Oct 15, 2024 | Director, 10%+ Owner |
| CAMP | Camp4 Therapeutics Corp | Oct 10, 2024 | 0 | $0 | 3 | Oct 10, 2024 | Director, 10%+ Owner |
| SKYE | Skye Bioscience, Inc. | Sep 11, 2024 | 6 | -$1.75M | 4 | Sep 13, 2024 | Director, 10%+ Owner |
| SKYE | Skye Bioscience, Inc. | Mar 13, 2024 | 1 | $4.5M | 4 | Mar 15, 2024 | Director, 10%+ Owner |
| SKYE | Skye Bioscience, Inc. | Feb 29, 2024 | 1 | $0 | 4 | Mar 4, 2024 | Director |
| SKYE | Skye Bioscience, Inc. | Jan 31, 2024 | 1 | $12M | 4 | Feb 2, 2024 | Director, 10%+ Owner |
| SKYE | Skye Bioscience, Inc. | Nov 6, 2023 | 1 | $0 | 4 | Nov 6, 2023 | Director |
| SKYE | Skye Bioscience, Inc. | Aug 25, 2023 | 1 | $0 | 4 | Aug 29, 2023 | Director |
| SKYE | Skye Bioscience, Inc. | Aug 18, 2023 | 6 | $8.78M | 4 | Aug 22, 2023 | Director, 10%+ Owner |
| SKYE | Skye Bioscience, Inc. | Aug 18, 2023 | 0 | $0 | 3 | Aug 22, 2023 | Director, 10%+ Owner |
| ELVN | Enliven Therapeutics, Inc. | Feb 23, 2023 | 1 | $0 | 4 | Apr 6, 2023 | Director, 10%+ Owner |
| ELVN | Enliven Therapeutics, Inc. | Feb 23, 2023 | 2 | $0 | 4 | Feb 27, 2023 | Director |
| ELVN | Enliven Therapeutics, Inc. | Feb 23, 2023 | 0 | $0 | 3 | Feb 27, 2023 | Director |
| PEARQ | Pear Therapeutics, Inc. | Dec 3, 2021 | 4 | $2M | 4 | Dec 7, 2021 | Director, 10%+ Owner |
| PEARQ | Pear Therapeutics, Inc. | Dec 3, 2021 | 0 | $0 | 3 | Dec 7, 2021 | Director, 10%+ Owner |